- AS8351
-
- $43.00 / 5mg
-
2026-02-02
- CAS:796-42-9
- Min. Order:
- Purity: 99.68%
- Supply Ability: 10g
|
| | N'-((2-hydroxynaphthalen-1-yl)methylene)isonicotinohydrazide Basic information | | Background |
| Product Name: | N'-((2-hydroxynaphthalen-1-yl)methylene)isonicotinohydrazide | | Synonyms: | AS8351;N'-((2-hydroxynaphthalen-1-yl)methylene)isonicotinohydrazide;NSC-51355;AS8351;AS 8351;NSC51355;NSC 51355;NSC-51355;NSC 51355;NSC51355;N'-[(2-hydroxynaphthalen-1-yl)methylidene]pyridine-4-carbohydrazide;N-[(Z)-(2-oxonaphthalen-1-ylidene)methyl]pyridine-4-carbohydrazide | | CAS: | 796-42-9 | | MF: | C17H13N3O2 | | MW: | 291.3 | | EINECS: | | | Product Categories: | API | | Mol File: | 796-42-9.mol |  |
| | N'-((2-hydroxynaphthalen-1-yl)methylene)isonicotinohydrazide Chemical Properties |
| storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | Soluble in DMSO (45 mg/ml); ethanol (10 mg/ml with warming) | | form | solid | | color | Yellow | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | | InChI | 1S/C17H13N3O2/c21-16-6-5-12-3-1-2-4-14(12)15(16)11-19-20-17(22)13-7-9-18-10-8-13/h1-11,21H,(H,20,22)/b19-11+ | | InChIKey | WQSHHAVECQJKLX-YBFXNURJSA-N | | SMILES | OC1=CC=C(C=CC=C2)C2=C1/C=N/NC(C3=CC=NC=C3)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | N'-((2-hydroxynaphthalen-1-yl)methylene)isonicotinohydrazide Usage And Synthesis |
| Description | AS-8351 is a histone demethylase inhibitor. It has been used in combination with CHIR99021 , A 83-01 , BIX01294 , SC-1 , Y-27632 (Item No. 10005583), OAC2 , SU 16f , and JNJ-10198409 to induce reprogramming of human fetal lung fibroblasts into functional cardiomyocytes. | | Uses | AS 8351 is used in the conversion of human fibroblasts into functional cardiomyocytes, which provides a promising source for regenerative therapy. | | Synthesis | H2La, H2Lb and H2Lc were synthesized using a standard method: equimolar amounts of isonicotinic acid hydrazide (pyridine-4-carbohydrazide) were reacted with the corresponding aldehydes (5-bromo-2-hydroxybenzaldehyde, 2-hydroxy-1-naphthylaldehyde, or 2,4-dihydroxybenzaldehyde) in ethanol by refluxing the compounds for 3 h, followed by cooling to room temperature. Crystals suitable for X-ray crystallographic analysis were obtained by slow evaporation of a dilute ethanol solution of the compound. | | in vitro | in a previous study, in order to identify indispensable factors for human fibroblasts, the authors removed combined compounds one by one and treated cells with the remaining compounds. results showed that the number of beating clusters was significantly reduced by removal of seven compounds including as8351. moreover, these seven compounds inlcuding as8351 were sufficient and necessary to induce cardiac reprogramming efficiently. the authors then investigated the role of the reprogramming compound of as8351 and the results showed that as8351 and its functional analogs could affect epigenetic modifications by competing with α- ketoglutarate for chelating iron/fe(ii) in some epigenetic enzymes, including the jmjc-domain-containing histone demethylases that require α-kg and iron as co-factors. in addition, the authors abrogated each of the 22 genes in the jmjc-kdm family by small hairpin rnas and found that only with kdm5b knockdown, or using a kdm5b inhibitor, pbit could phenocopy as8351 in generating cicms, indicating that it might be a target of as8351 [1]. | | IC 50 | KDM5 | | Background | AS-8351 is a small-molecule inhibitor of lysine demethylase 5B, which demethylates Lys4 of histone H3. AS-8351 is also involved in cell fate decisions and is overexpressed in a variety of human cancers. Overexpression of JARID1B is seen in breast cancer and correlates with increased metastasis. AS-8351 treatment of breast cancer cells inhibited breast cancer cell proliferation and migration. Additionally, AS-8351 reversed epithelial-mesenchymal transition and decreased fatty acid synthase and ATP citrate lyase protein levels in breast cancer cells. JARID1B is overexpressed in Ewing sarcoma and correlates with poor outcomes in EWS patients. Inhibition of JARID1B by AS-8351 in EWS cells reduced cell proliferation and increased apoptosis and cell cycle arrest. AS-8351 inhibited tumor growth in EWS mouse xenografts, suggesting a possible role for AS-8351 in the clinical treatment of this disease. | | References | [1] NAN CAO. Conversion of human fibroblasts into functional cardiomyocytes by small molecules[J]. Science, 2016, 352 6290. DOI:10.1126/science.aaf1502 |
| | N'-((2-hydroxynaphthalen-1-yl)methylene)isonicotinohydrazide Preparation Products And Raw materials |
|